Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

PolyPid Ltd.

Contributing Author

Recent Articles by PolyPid Ltd.

Dec-03	PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission PYPD GlobeNewswire
Nov-25	PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 PYPD GlobeNewswire
Nov-12	PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results PYPD GlobeNewswire
Nov-06	PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year" PYPD GlobeNewswire
Oct-29	PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 PYPD GlobeNewswire
Sep-30	PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress PYPD GlobeNewswire
Sep-17	PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference PYPD GlobeNewswire
Sep-16	PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀ PYPD GlobeNewswire
Sep-03	PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference PYPD GlobeNewswire
Sep-02	PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference PYPD GlobeNewswire
Aug-13	PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results PYPD GlobeNewswire
Aug-12	PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer PYPD GlobeNewswire
Jul-30	PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 PYPD GlobeNewswire
Jul-15	PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market PYPD GlobeNewswire
Jun-16	PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PYPD GlobeNewswire
Jun-09	PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints PYPD GlobeNewswire
Jun-06	PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 PYPD GlobeNewswire
May-20	PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 PYPD GlobeNewswire
May-14	PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PYPD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.